Roche, Basel, Switzerland, has received the CE mark for its Accu Chek Solo micropump system. In the coming weeks, the company will initiate the pilot commercialization phase for its innovative insulin delivery system in Austria, Poland, Switzerland, and the United Kingdom. The company is also conducting a clinical study of the micropump system in several European countries.
“This important milestone will enable us to further expand access to insulin pump therapy to those people with diabetes who can benefit most from this therapy option so they can spend more time in their ideal target range and experience an improved quality of life,” says Roland Diggelmann, CEO of Roche Diagnostics. “The new modular design of our Accu-Chek Solo micropump system responds to the needs of people with diabetes for more discretion and flexibility.”
Roland Diggelmann, Roche Diagnostics.
The Accu-Chek Solo micropump system allows for convenience and personalization in insulin pump therapy while contributing to more targeted and effective diabetes management. It offers the functionalities of a traditional insulin pump alongside the technological advance of tube-free insulin delivery.
The system consists of two parts: a small, lightweight and semidisposable insulin micropump, and a fully featured remote control incorporating blood glucose monitoring and bolus advice. The system provides bolus insulin dosing from the remote control or directly from the pump as well as the option to detach and reattach the pump without wasting insulin. In addition, the system connects to Roche Diabetes Care’s digital solutions such as the Accu-Chek Smart Pix system, providing decision and therapy support at the doctor’s office with a proven tool for efficient, effective, and personalized diabetes management.1,2
To learn more, visit Roche.
References
1. Weissmann J, Mueller A, Messinger D, Parkin CG, Amann-Zalan I. Improving the quality of outpatient diabetes care using an information management system. J Diabetes Sci Technol. 2016;10(1):76–84; doi: 10.1177/1932296815595984.
2. Dänschel I, Dänschel W, Heinemann L, Messinger D, Weissmann J, Kulzer B. Effects of integrated personalized diabetes management: results of the PDM-ProValue study program [poster, online]. Poster 1261 presented at the Primary Care Diabetes Europe conference, Barcelona, April 13–14, 2018. Available at: http://pcde2018.nubuser.com/page/2. Accessed August 17, 2018.
